Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Brazil approves Beyonttra (acoramidis) to treat ATTR-CM, showing strong clinical benefits in heart disease patients.
BBIO
$82.33
-$1.77 -2.10%

Brazil approves Beyonttra (acoramidis) to treat ATTR-CM, showing strong clinical benefits in heart disease patients.

Market News
06 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Brazil's health regulator ANVISA has approved Beyonttra (acoramidis) for treating transthyretin amyloidosis cardiomyopathy (ATTR-CM) in adults. This approval follows positive Phase 3 trial results showing acoramidis significantly reduces cardiovascular hospitalizations and deaths, improves survival, and maintains quality of life. The drug, already approved in the US, EU, UK, Japan, and Switzerland, offers near-complete stabilization of the disease. Commercialization in Brazil will begin in late 2026, expanding patient access to this transformative treatment.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App